Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Current Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Total Current Liabilities for 5 consecutive years, with $6.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 57.66% to $6.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.0 million, a 57.66% decrease, with the full-year FY2024 number at $13.8 million, up 45.98% from a year prior.
  • Total Current Liabilities was $6.0 million for Q3 2025 at Mereo BioPharma, down from $7.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $16.9 million in Q4 2021 to a low of $6.0 million in Q3 2025.
  • A 4-year average of $11.3 million and a median of $11.0 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 49.48% in 2021, then tumbled 57.66% in 2025.
  • Mereo BioPharma's Total Current Liabilities stood at $16.9 million in 2021, then tumbled by 43.89% to $9.5 million in 2023, then skyrocketed by 45.98% to $13.8 million in 2024, then plummeted by 56.56% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Total Current Liabilities are $6.0 million (Q3 2025), $7.6 million (Q2 2025), and $7.5 million (Q1 2025).